http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2166944-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e210d98e194586a4e53828e61f8a9ae9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8073632c63fdeed1051a30a2f77d4102 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14 |
| filingDate | 1998-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2001-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2001-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2166944-C2 |
| titleOfInvention | Plasma substitute solution with hemocorrecting and immunomodulating properties |
| abstract | FIELD: medicine, pharmacy. SUBSTANCE: invention relates to pharmaceutical agents used for treatment of patients with severe acute and chronic damages resulting to blood loss or depletion of its functional properties and accompanying immunodeficiency state. Plasma substitute solution has isotonic solution and DNA sodium salt additionally obtained from animal raw with mean molecular mass (1.5-550) x 10 3 Da and hyperchromic effect 28-46% taken in the amount 5 x 10 -5 g/1 l of isotonic solution. Except for the basic curative effect this agent stimulates hemopoiesis and myelopoiesis being without adverse effects. EFFECT: increase percent of viability, decreased time of patients treatment. 5 tbl, 1 ex |
| priorityDate | 1998-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 90.